6-((3S,4S)-4-Methyl-1-((2-methylpyrimidin-5-YL)methyl)pyrrolidin-3-YL)-1-(tetrahydro-2H-pyran-4-YL)-1,5-dihydro-4H-pyrazolo[3,4-D]pyrimidin-4-one → 3-methyl-6-{(3S,4S)-4-methyl-1-[(2-methylpyrimidin-5-yl)methyl]pyrrolidin-3-yl}-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one

Participants

Reaction Steps

Following the procedure for the preparation of 6-{(3S,4S)-4-methyl-1-[(2-methylpyrimidin-5-yl)methyl]pyrrolidin-3-yl}-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one but substituting 3-methyl-6-[(3S,4S)-4-methylpyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one provided the title compound. 400 MHz 1H NMR (CDCl3) δ 8.63 (s, 2H), 4.74-4.68 (m, 1H), 4.11-4.08 (m, 2H), 3.74-3.63 (m, 2H), 3.60-3.52 (m, 2H), 3.28 (t, J=8.3 Hz, 1H), 3.03 (d, J=9.5 Hz, 1H), 2.85-2.83 (m, 1H), 2.71 (s, 3H), 2.65-2.61 (m, 1H), 2.53 (s, 3H), 2.48-2.29 (m, 2H), 1.98 (t, J=8.7 Hz, 1H), 1.87-1.80 (m, 3H), 1.19 (d, J=7.1 Hz, 3H). MS: (M+H m/z 424.2).

Provenance & Evidence